Delayed Puberty Medical Services in China

Delayed puberty is a clinical condition characterized by the absence of secondary sexual development by age 13 in girls (no breast development) or age 14 in boys (no testicular enlargement ≥4 mL or 2.5 cm in length). It represents a deviation from the normal pubertal timing spectrum and may reflect either a benign, self-limited variant—constitutional delay of growth and puberty (CDGP)—or an underlying pathological disorder affecting the hypothalamic-pituitary-gonadal (HPG) axis. Pathogenesis is broadly categorized into three groups: central (hypogonadotropic) causes—including functional suppression (e.g., chronic illness, malnutrition, excessive exercise, psychosocial stress), congenital deficiencies (e.g., Kallmann syndrome, idiopathic hypogonadotropic hypogonadism), or acquired lesions (e.g., craniopharyngioma, traumatic brain injury); peripheral (hypergonadotropic) causes—such as primary gonadal failure (e.g., Turner syndrome in females, Klinefelter syndrome in males, chemotherapy-induced gonadal damage); and other endocrine disorders—including hypothyroidism, hyperprolactinemia, Cushing syndrome, or growth hormone deficiency. Epidemiologically, delayed puberty affects approximately 2–3% of adolescents, with CDGP accounting for ~70–80% of cases in males and ~40–50% in females; true pathological causes are less common but require timely identification to prevent long-term sequelae. Key risk factors include family history of delayed puberty, chronic systemic diseases (e.g., inflammatory bowel disease, cystic fibrosis), eating disorders, intense athletic training, genetic syndromes, and prior cranial irradiation or chemotherapy. Psychosocial impact is profound: affected adolescents often experience heightened anxiety, social withdrawal, low self-esteem, body image distress, and academic disengagement due to perceived physical immaturity relative to peers. Untreated pathological forms may lead to osteopenia, short adult stature, infertility, and metabolic complications later in life. Early evaluation—including detailed history, auxology, bone age assessment (hand-wrist radiograph), hormonal profiling (LH, FSH, estradiol/testosterone, AMH, inhibin B, thyroid function, prolactin), and targeted imaging (e.g., pituitary MRI if central cause suspected)—is essential to differentiate CDGP from organic disease. Multidisciplinary care involving pediatric endocrinologists, psychologists, nutritionists, and reproductive specialists optimizes outcomes and supports holistic quality of life restoration.

Delayed puberty is defined as the absence of testicular enlargement (testicular volume <4 mL or length <2.5 cm) in boys by age 14 years, or the lack of breast development (Tanner stage B2) in girls by age 13 years, or the absence of menarche by age 15 years or more than 3 years after the onset of breast development. It represents a heterogeneous clinical presentation arising from disruptions in the hypothalamic–pituitary–gonadal (HPG) axis, constitutional factors, or systemic disease. Common causes fall into three broad categories: constitutional delay of growth and puberty (CDGP), functional hypogonadotropic hypogonadism (FHH), and organic central or peripheral disorders. CDGP is the most frequent cause—accounting for approximately 70–80% of cases—and reflects a benign, heritable variant of normal pubertal timing characterized by delayed activation of the HPG axis without underlying pathology. FHH, often secondary to chronic energy deficit, excessive physical exertion, or psychosocial stress, results in reversible suppression of gonadotropin-releasing hormone (GnRH) pulsatility, leading to low luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroid levels. Organic central causes include congenital anomalies (e.g., Kallmann syndrome—characterized by anosmia and GnRH neuron migration defects due to mutations in ANOS1, FGFR1, PROK2/PROKR2), acquired hypothalamic or pituitary lesions (craniopharyngioma, germinoma, traumatic brain injury, radiation), and inflammatory/infiltrative conditions (sarcoidosis, histiocytosis). Peripheral causes involve primary gonadal failure (e.g., Turner syndrome [45,X], Klinefelter syndrome [47,XXY], gonadal dysgenesis, chemotherapy-induced damage) or enzymatic defects in steroidogenesis (e.g., 17α-hydroxylase deficiency, aromatase deficiency). Triggers for delayed puberty may be acute or subacute, including significant weight loss (>10% body weight), initiation of intense endurance training, onset of chronic illness (e.g., inflammatory bowel disease, cystic fibrosis, renal failure), or psychological trauma. Risk factors encompass both modifiable and non-modifiable elements. Genetic factors are prominent: CDGP demonstrates strong familial aggregation, with up to 70% of affected individuals reporting a family history of delayed puberty; genome-wide association studies implicate loci near LIN28B, MKRN3, DLK1, and TAC3/TACR3 in pubertal timing regulation. Pathogenic variants in MKRN3 (maternally imprinted, paternally expressed) cause autosomal dominant central precocious puberty when gain-of-function, but loss-of-function or deletions contribute to delayed onset. Epigenetic dysregulation of imprinted genes at 14q32 (DLK1–MEG3 locus) is increasingly recognized in idiopathic hypogonadotropic hypogonadism. Environmental factors significantly influence pubertal tempo: chronic undernutrition, particularly protein-energy malnutrition and micronutrient deficiencies (e.g., zinc, iron, vitamin D), suppress GnRH secretion via leptin and kisspeptin pathways. Endocrine-disrupting chemicals—including bisphenol A (BPA), phthalates, and persistent organic pollutants—may interfere with hypothalamic neuroendocrine signaling or gonadal steroidogenesis. Socioeconomic adversity, childhood maltreatment, and institutional deprivation correlate with later pubertal onset, likely mediated through chronic hypothalamic–pituitary–adrenal (HPA) axis activation and elevated cortisol, which inhibits GnRH neuronal activity. Obesity exerts dual effects: while adiposity generally advances puberty in girls via increased leptin and estradiol aromatization, severe obesity in boys may delay puberty due to hyperinsulinemia, inflammation, and altered sex hormone-binding globulin (SHBG) dynamics. Other medical risk factors include untreated celiac disease (inducing malabsorption and immune-mediated hypothalamic dysfunction), poorly controlled type 1 diabetes (with chronic hyperglycemia impairing gonadotropin pulsatility), and long-term glucocorticoid therapy. Iatrogenic contributors include opioid use (which directly suppresses GnRH release), dopamine agonists, and certain antipsychotics. Accurate etiological differentiation requires comprehensive evaluation—including auxology, bone age assessment, hormonal profiling (basal LH, FSH, testosterone/estradiol, AMH, inhibin B), imaging (pituitary MRI), and targeted genetic testing—given the profound implications for fertility, bone health, metabolic programming, and psychosocial development.

Delayed puberty is defined as the absence of secondary sexual characteristics by age 13 in girls (no breast development) or age 14 in boys (no testicular enlargement ≥4 mL volume or ≥2.5 cm in longest diameter). It represents a heterogeneous clinical presentation rooted in disruptions of the hypothalamic–pituitary–gonadal (HPG) axis and warrants comprehensive endocrine evaluation. Early symptoms are often subtle and may be overlooked without systematic assessment. In girls, early signs include persistent prepubertal height velocity (typically <5 cm/year after age 10), absence of thelarche by age 13, lack of pubic hair (pubarche) by age 14, and continued prepubertal body habitus—characterized by narrow hips, absence of fat redistribution, and linear growth pattern without a pubertal growth spurt. In boys, early indicators comprise no testicular enlargement by age 14, absence of phallic growth, lack of facial or axillary hair, persistently high-pitched voice, and failure to demonstrate accelerated linear growth or muscle mass accrual. Notably, constitutional delay of growth and puberty (CDGP), the most common cause, presents with a strong family history of delayed maturation, prepubertal bone age delay (often >2 years behind chronological age), and preserved growth velocity relative to peers—distinguishing it from pathological causes.

Typical symptoms reflect progressive failure of gonadotropin-driven sex steroid production. In girls, this manifests as primary amenorrhea (no menarche by age 15 despite evidence of prior breast development), arrested breast development (Tanner stage B1–B2 for >2 years), minimal or absent pubic/axillary hair (Tanner P1–P2), and uterine hypoplasia on pelvic ultrasound (length <3.5 cm, volume <1.5 mL). In boys, typical features include micropenis (<2.5 cm stretched penile length at birth or <7 cm in adolescence), cryptorchidism (if undescended testes persist beyond infancy), small firm testes (<4 mL volume), eunuchoid proportions (arm span > height by >5 cm, upper-to-lower segment ratio <0.85), and absence of voice deepening or laryngeal prominence. Both sexes exhibit delayed epiphyseal fusion, resulting in prolonged growth potential but risk of tall stature with disproportionately long limbs if untreated.

Accompanying symptoms provide critical diagnostic clues. Neurological manifestations—including anosmia (suggestive of Kallmann syndrome), sensorineural hearing loss (CHARGE syndrome), nystagmus, or cerebellar ataxia—point to congenital hypothalamic malformations or syndromic etiologies. Chronic systemic symptoms such as fatigue, weight loss, polyuria/polydipsia, or visual field defects raise suspicion for intracranial pathology (e.g., craniopharyngioma, germinoma) or chronic disease (e.g., inflammatory bowel disease, celiac disease, renal insufficiency). Endocrine comorbidities include short stature disproportionate to parental height, hypothyroidism (fatigue, cold intolerance, constipation), adrenal insufficiency (hypotension, hyperpigmentation, salt craving), or diabetes mellitus (polyuria, weight loss, acanthosis nigricans). Psychosocial sequelae—such as social withdrawal, academic underperformance, low self-esteem, anxiety, and depression—are highly prevalent and require integrated psychological support.

Complications arise from both the underlying pathophysiology and prolonged hormonal deficiency. Osteopenia and osteoporosis develop due to prolonged estrogen/testosterone deficiency, increasing fracture risk during adolescence and predisposing to premature bone loss in adulthood. Impaired peak bone mass acquisition is particularly concerning, as >90% of skeletal mass is accrued by age 18. Infertility is nearly universal in untreated gonadotropin deficiency and common in hypergonadotropic states (e.g., Turner or Klinefelter syndromes). Cardiovascular risks emerge over time, including adverse lipid profiles (elevated LDL, reduced HDL), endothelial dysfunction, and increased carotid intima-media thickness. Psychosocial morbidity extends into adulthood, with documented higher rates of interpersonal difficulties, reduced educational attainment, and diminished quality of life. In males with untreated hypogonadism, decreased lean body mass, increased adiposity, and insulin resistance may accelerate metabolic syndrome.

Diagnosis relies on a structured, stepwise approach. Initial evaluation includes detailed history (family/pubertal history, chronic illness, medications, psychosocial stressors) and physical examination (height, weight, BMI, Tanner staging, dysmorphic features, neurological exam, testicular volume via Prader orchidometer). First-line laboratory testing comprises serum LH, FSH, estradiol (girls), testosterone (boys), TSH, free T4, IGF-1, complete blood count, and metabolic panel. A bone age radiograph (left hand/wrist) objectively assesses skeletal maturation. If central causes are suspected, MRI of the brain and pituitary with contrast is mandatory to exclude structural lesions. Additional testing includes GnRH stimulation test (blunted LH/FSH response suggests hypothalamic/pituitary failure), karyotype (to detect Turner [45,X], Klinefelter [47,XXY], or mosaicisms), and genetic panels (e.g., ANOS1, FGFR1, PROKR2 for Kallmann; CHD7 for CHARGE). Pelvic ultrasound in girls evaluates uterine size and ovarian morphology; scrotal ultrasound in boys assesses testicular position, volume, and echotexture.

Differential diagnosis must distinguish between central (hypogonadotropic) and peripheral (hypergonadotropic) etiologies. Central causes include CDGP (normal or mildly elevated LH/FSH, low sex steroids, delayed bone age), functional hypothalamic amenorrhea (often linked to excessive exercise, disordered eating, or chronic stress), idiopathic hypogonadotropic hypogonadism (IHH), and organic CNS disorders (tumors, trauma, radiation, infiltrative diseases). Peripheral causes involve primary gonadal failure: chromosomal disorders (Turner, Klinefelter), autoimmune oophoritis/orchitis, chemotherapy/radiation-induced damage, and enzymatic defects (e.g., 17α-hydroxylase deficiency). Systemic illnesses—including celiac disease, cystic fibrosis, sickle cell disease, and chronic kidney disease—must be excluded, as they induce functional delay via energy deficit or inflammation. Endocrinopathies like congenital adrenal hyperplasia (non-classic forms may present with oligomenorrhea but not delay), hyperprolactinemia (causing galactorrhea-amenorrhea), and severe primary hypothyroidism (elevated TRH stimulating prolactin and suppressing GnRH) require targeted investigation. Finally, exogenous factors—such as glucocorticoid therapy, opioid use, or anabolic steroid abuse—must be meticulously reviewed. Accurate classification guides management: sex steroid replacement for induction of puberty, gonadotropin therapy for fertility preservation, and multidisciplinary care addressing nutritional, psychological, and long-term endocrine health.

Delayed puberty is defined as the absence of testicular enlargement (testicular volume <4 mL or diameter <2.5 cm) in boys by age 14 years, or lack of breast development (Tanner stage B2) in girls by age 13 years. It may represent a benign constitutional delay of growth and puberty (CDGP), functional hypogonadotropic hypogonadism (e.g., due to chronic illness, malnutrition, excessive exercise, or psychosocial stress), or organic disorders including congenital hypogonadotropic hypogonadism (CHH), hypergonadotropic hypogonadism (e.g., Klinefelter or Turner syndromes), central nervous system tumors, or genetic syndromes. Accurate diagnosis—requiring detailed history, physical examination, bone age assessment, hormonal profiling (LH, FSH, testosterone/estradiol, AMH, inhibin B), pituitary MRI when indicated, and genetic testing (e.g., ANOS1, FGFR1, PROKR2, CHD7)—is essential before initiating therapy.

Conservative management is first-line for confirmed constitutional delay. This includes comprehensive nutritional optimization—ensuring adequate caloric intake, protein, zinc, vitamin D, and iron—particularly critical in adolescents with relative energy deficiency in sport (RED-S) or chronic gastrointestinal disease. Psychosocial support is integral: counseling addresses body image concerns, peer-related anxiety, academic stress, and potential depression or social withdrawal. Regular longitudinal monitoring every 6–12 months assesses growth velocity, pubertal staging (Tanner scale), bone age progression, and psychosocial adaptation. In CDGP, spontaneous puberty typically emerges within 1–2 years; observation without intervention remains appropriate when no red flags (e.g., anosmia, micropenis, cryptorchidism, neurologic symptoms, or growth failure) are present.

Pharmacologic intervention is indicated when delayed puberty causes significant psychosocial distress, compromises peak bone mass accrual, or reflects underlying pathology. For boys with CDGP or mild CHH, low-dose testosterone enanthate or cypionate (25–50 mg intramuscularly every 4 weeks for 4–6 months) induces virilization and stimulates endogenous gonadotropin secretion via hypothalamic-pituitary feedback modulation. In girls, estradiol valerate (0.5–1.0 mg orally daily for 6–12 months, gradually increased to adult replacement doses) initiates breast development and uterine priming; progesterone (e.g., micronized progesterone 100 mg daily for 10–12 days per cycle) is added after 12–18 months or upon breakthrough bleeding to induce cyclical endometrial shedding. For patients with documented CHH requiring fertility preservation, pulsatile GnRH therapy (via portable subcutaneous pump) or gonadotropin regimens (hCG + recombinant FSH) are employed under specialist supervision. Aromatase inhibitors (e.g., letrozole) are not recommended for routine use in delayed puberty due to insufficient long-term safety data and lack of proven benefit on final height or bone health.

Surgical treatment is rarely indicated for delayed puberty itself but becomes necessary when an underlying structural lesion is identified. Pituitary adenomas, craniopharyngiomas, or hypothalamic hamartomas causing compressive hypogonadotropic hypogonadism require neurosurgical evaluation. Transsphenoidal resection is standard for non-invasive, hormonally inactive microadenomas or symptomatic macroadenomas. In cases of ectopic posterior pituitary or optic pathway gliomas, multidisciplinary neuro-oncology input guides timing and modality of intervention. Cryptorchidism—present in up to 15% of boys with delayed puberty—warrants orchidopexy before age 18 months if persistent beyond infancy; late correction (>10 years) does not reverse germ cell loss but mitigates malignancy risk. Surgical sex assignment is never indicated solely for delayed puberty and requires rigorous ethical review only in complex differences of sex development (DSD) contexts.

China offers distinct advantages in the multidisciplinary management of delayed puberty. First, integrated endocrine-pediatric-gynecologic-neurosurgical teams operate within tiered national healthcare frameworks, enabling rapid referral from primary care to tertiary centers such as Peking Union Medical College Hospital or Shanghai Children’s Medical Center. Second, China’s National Rare Diseases Registry and Genomic Initiative facilitate timely access to next-generation sequencing panels for CHH and DSD diagnostics, reducing diagnostic odysseys. Third, cost-effective biosimilar gonadotropins and domestically manufactured estradiol/testosterone formulations improve treatment accessibility. Fourth, standardized clinical pathways endorsed by the Chinese Endocrine Society ensure evidence-based, protocol-driven care across provinces. Fifth, digital health platforms (e.g., WeDoctor, Ping An Good Doctor) support remote monitoring of growth parameters, medication adherence, and mental health screening—critical for rural populations. Finally, large-scale longitudinal cohort studies (e.g., the China Adolescent Growth Project) generate real-world data on natural history and treatment outcomes unique to East Asian phenotypes.

Recovery and long-term follow-up emphasize metabolic and skeletal health maintenance. Patients completing induction therapy should transition to full sex hormone replacement aligned with chronological age and bone maturation—testosterone (100–150 mg IM weekly or transdermal gel) or estradiol (1–2 mg/day oral or transdermal) plus cyclic progesterone. Dual-energy X-ray absorptiometry (DXA) is recommended at completion of puberty to assess bone mineral density (BMD); those with Z-scores <−2.0 warrant calcium (1,200 mg/day), vitamin D (1,000–2,000 IU/day), weight-bearing exercise prescription, and endocrinology re-evaluation. Fertility counseling must begin early: semen analysis in postpubertal males and ovarian reserve testing (AMH, AFC) in females guide future reproductive planning. Annual assessments of cardiovascular risk factors (lipid profile, glucose, blood pressure), thyroid function, and pituitary axes remain essential, particularly in CHH or prior cranial irradiation. Psychosocial resilience is reinforced through peer-support networks, school liaison services, and cognitive-behavioral strategies targeting self-efficacy and identity integration. With timely, individualized intervention, >95% of adolescents with constitutional delay achieve normal adult height, sexual function, and psychosocial adaptation; even those with organic causes attain high-quality life outcomes when managed within China’s evolving precision endocrinology ecosystem.